Specialized pharmaceutical company Xeris (NASDAQ: XERS) pops amid launching Gvoke HypoPen for patients with serious Hypoglycemia. Now penny XERS is reaching $4.213 on over 8 million shares of daily volume.
Users can inject Hypopen by themselves as the COVID-19 makes people stay distant. This innovative product is saving a huge time of medics while decreasing the sugar level in users’ blood.
Q3 revenue of Xeris will surely rise, consequently, earnings will soar by wiping the negative EPS that scares long term investors.
Under $5 healthcare stock may look suspicious but considering its new product as a positive factor could make any investor buy XERS before it becomes expensive.
Finance and Tech Contributor